Vol 10, No 5 (2021)
Research paper
Published online: 2021-03-05

open access

Page views 6292
Article views/downloads 315
Get Citation

Connect on Social Media

Connect on Social Media

Autoantibodies in Moroccan patients with type 1 diabetes: Which one to choose?

Faycal El Guendouz1, Sara Derrou1, Yousra Benabdelfedil1, Hassan Ouleghzal1, Somaya Safi1
Clin Diabetol 2021;10(5):403-406.

Abstract

Background. Immunological investigations are intend-ed for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population.
Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 autoantibody (GADA), 46% for insulinoma-associated protein 2 autoantibody (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients.
Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence.

Article available in PDF format

View PDF Download PDF file

References

  1. Leroy C, Fajardy I, Fontaine P. Pancreas-specific autoimmune markers in clinical practice. Correspondances en Métabolismes Hormones Diabètes et Nutrition 17. 2013; 3: 48–53.
  2. Kasimiotis H, Fida S, Rowley MJ, et al. Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. Autoimmunity. 2001; 33(2): 95–101.
  3. Fida S, Myers M, Mackay IR, et al. Antibodies to diabetes-associated autoantigens in Indian patients with Type 1 diabetes: prevalence of anti-ICA512/IA2 and anti-SOX13. Diabetes Research and Clinical Practice. 2001; 52(3): 205–211.
  4. Boitard C. Pancreatic islet autoimmunity. Presse Med. 2012; 41(12 P 2): e636–e650.
  5. Pardini VC, Mourao DM, Nascimento PD, et al. Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients. Braz J Med Biol Res. 1999; 32(10): 1195–1198.
  6. Mortensen HB, Swift PGF, Holl RW, et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes. 2010; 11(4): 218–226.
  7. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia. 1999; 42(1): 3–14.
  8. Borg H, Gottsäter A, Fernlund P, et al. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002; 51(6): 1754–1762.
  9. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem. 2011; 57(2): 168–175.
  10. Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003; 26(2): 452–457.